Want to see CH:KURN full AI Analyst Report?

Kuros Biosciences (KURN) Price & Analysis

10 Followers

KURN Stock Chart & Stats

CHF19.80

CHF0.62(3.13%)

At close: Jul 27 4:00 PM EDT

CHF19.80

CHF0.62(3.13%)

Day’s Range― - ―

52-Week RangeCHF17.69 - CHF34.20

Previous CloseN/A

Volume158.99K

Average Volume (3M)128.87K

Market Cap

CHF848.98M

Enterprise ValueCHF764.71

Total Cash (Recent Filing)CHF7.85M

Total Debt (Recent Filing)CHF11.01M

Price to Earnings (P/E)118.2

Beta1.43

Next Earnings

Mar 17, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.18

Shares Outstanding39,671,734

10 Day Avg. Volume110,510

30 Day Avg. Volume128,868

Financial Highlights & Ratios

PEG Ratio-3.21

Price to Book (P/B)15.78

Price to Sales (P/S)8.71

P/FCF Ratio-439.50

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

CHF32.50

Price Target Upside64.14% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)0.36

Revenue Forecast (FY)CHF207.82M

Bulls Say, Bears Say

Bulls Say

Rapid Revenue Growth And Market ExpansionRapid sales growth, broader distribution and rising surgeon utilization indicate strong product adoption in the spine market. Continued account expansion can support durable procedure-driven demand and improve operating leverage as the commercial platform scales.

Clinical Evidence Supports Product DifferentiationPublished clinical outcomes in a high-risk population provide support for MagnetOs effectiveness and its value proposition versus alternatives. Additional Level 1 evidence could strengthen surgeon confidence, institutional adoption and access to broader indications.

High Margins And Conservative Balance SheetVery high gross margins provide a strong foundation for future operating leverage, while minimal debt reduces financing risk. This balance-sheet flexibility can support manufacturing investment and commercial expansion without excessive dependence on external capital.

Bears Say

Weak Cash Conversion And Working-Capital PressureProfitability has not yet translated consistently into cash generation, while receivables absorb substantial liquidity. If working-capital intensity persists during expansion, Kuros may face greater funding sensitivity despite its low debt burden.

Manufacturing Ramp And Margin Execution RiskLocalized dual-source production may improve resilience over time, but the transition introduces execution, utilization and cost risks. Ramp dilution and transformation spending could temporarily offset scale benefits and delay progress toward the targeted margin structure.

Clinical And International Expansion Remain IncompleteKey comparative trials have not yet produced complete results, leaving parts of the clinical adoption case still to be validated. International regulatory and timing volatility also limit diversification until broader evidence and market access are established.

Kuros Biosciences News

Kuros Biosciences initiated with a Buy at UBS

UBS analyst Tanya Hansalik initiated coverage of Kuros Biosciences (CSBTF) with a Buy rating and CHF 33 price...

22d ago

Kuros Biosciences Earnings Call Signals Profitable Growth

Kuros Biosciences (($CH:KURN)) has held its Q2 earnings call. Read on for the main highlights of the call....

5d ago

Kuros Biosciences Posts Strong H1 Growth as MagnetOs Gains Orthobiologics Share

The latest update is out from Kuros Biosciences ( ($CH:KURN) ). Kuros Biosciences reported a 45% year-on-year increase...

7d ago

Kuros Biosciences initiated with a Buy at Berenberg

Berenberg initiated coverage of Kuros Biosciences (CSBTF) with a Buy rating and CHF 32 price target Kuros Biosciences...

1M ago

Kuros Biosciences posts 51% Q1 sales surge on MagnetOs growth and manufacturing expansion

Kuros Biosciences ( ($CH:KURN) ) has issued an announcement. Kuros Biosciences reported a 51% year-on-year increase in total...

4M ago

Kuros Biosciences Hits Record Sales and First Profit as MagnetOs Fuels Global Expansion

Kuros Biosciences ( ($CH:KURN) ) just unveiled an update. Kuros Biosciences reported a 72% jump in 2025 medical...

5M ago

Kuros Biosciences’ MagnetOs Study: A Potential Game-Changer in Spinal Fusion

Kuros Biosciences (($CSBTF)) announced an update on their ongoing clinical study. Study Overview: Kuros Biosciences is conducting a...

10M ago

CSBTF

Kuros Biosciences’ Clinical Study on MagnetOs Flex Matrix: A Potential Game-Changer in Spinal Fusion

Kuros Biosciences (($CSBTF)) announced an update on their ongoing clinical study. Kuros Biosciences is conducting a phase IV...

10M ago

CSBTF

Kuros Biosciences Reports Strong Revenue Growth and Strategic Expansion

The latest announcement is out from Kuros Biosciences ( ($CH:KURN) ). Kuros Biosciences announced a 77% year-over-year increase...

10M ago

Kuros Biosciences Investigates Allegations Against Former Board Member

Kuros Biosciences ( ($CH:KURN) ) has shared an update. Kuros Biosciences is addressing media inquiries regarding the resignation...

11M ago

Kuros Biosciences Announces Board of Directors Changes

Kuros Biosciences ( ($CH:KURN) ) has provided an announcement. Kuros Biosciences announced changes to its Board of Directors,...

12M ago

Kuros Biosciences Reports Strong Revenue Growth in 2025

Kuros Biosciences ( ($CSBTF) ) has released its Q2 earnings. Here is a breakdown of the information Kuros...

1y ago

KURN FAQ

What was Kuros Biosciences Ltd.’s price range in the past 12 months?

Kuros Biosciences Ltd. lowest stock price was CHF17.69 and its highest was CHF34.20 in the past 12 months.

What is Kuros Biosciences Ltd.’s market cap?

Kuros Biosciences Ltd.’s market cap is CHF848.98M.

When is Kuros Biosciences Ltd.’s upcoming earnings report date?

Kuros Biosciences Ltd.’s upcoming earnings report date is Mar 17, 2027 which is in 210 days.

How were Kuros Biosciences Ltd.’s earnings last quarter?

Kuros Biosciences Ltd. released its earnings results on Aug 13, 2026. The company reported CHF0.06 earnings per share for the quarter, beating the consensus estimate of CHF0.058 by CHF0.002.

Is Kuros Biosciences Ltd. overvalued?

According to Wall Street analysts Kuros Biosciences Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Kuros Biosciences Ltd. pay dividends?

Kuros Biosciences Ltd. does not currently pay dividends.

What is Kuros Biosciences Ltd.’s EPS estimate?

Kuros Biosciences Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Kuros Biosciences Ltd. have?

Kuros Biosciences Ltd. has 39,671,734 shares outstanding.

What happened to Kuros Biosciences Ltd.’s price movement after its last earnings report?

Kuros Biosciences Ltd. reported an EPS of CHF0.06 in its last earnings report, beating expectations of CHF0.058. Following the earnings report the stock price went up 0.609%.

Which hedge fund is a major shareholder of Kuros Biosciences Ltd.?

Currently, no hedge funds are holding shares in CH:KURN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Kuros Biosciences Ltd.

Kuros Biosciences AG functions as a biopharmaceutical enterprise, dedicated to both the development and market introduction of advanced therapeutic solutions for tissue regeneration and bone repair. Its operations span across the United States, the European Union, and other global regions. The company's business activities are structured into three main segments: Medical Devices, Pharmaceuticals, and a Legacy Portfolio. Its orthobiologics product line includes MagnetOs Granules and MagnetOs Putty, available in EU and US markets for various orthopedic, spinal, and dental applications. Within its fibrin/PTH orthobiologics pipeline, KUR-111 has successfully completed a Phase 2b clinical trial for treating tibial plateau fractures. Similarly, KUR-113 has concluded its Phase 2b clinical trial for tibial shaft fractures and is currently undergoing a Phase II trial for spinal interbody fusion procedures. Additionally, Kuros offers sealant products such as Neuroseal, a synthetic tissue sealant marketed in the EU and US, engineered to prevent cerebrospinal fluid leakage after cranial or spinal surgeries. The company also engages in a collaborative endeavor with Checkmate Pharmaceuticals LLC for the advancement of CYT003, intended for oncology treatments. Kuros Biosciences AG is headquartered in Schlieren, Switzerland.

Kuros Biosciences (KURN) Earnings & Revenues

Historic Earnings Reports

KURN Company Deck

KURN Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call communicated a strong set of operational and financial achievements (robust +45% H1 revenue growth, first sustained half‑year profitability with CHF 12.5M adjusted EBITDA and CHF 4.4M net profit, improving gross margins, strong clinical evidence and a clear midterm revenue/margin target). These positives are tempered by planned near‑term investments and transformation costs, expected dilution from the U.S. manufacturing ramp, lumpiness in international revenue, and working capital accumulation that creates short-term liquidity sensitivity. On balance, the transformational investments are framed as deliberate and the company maintained conservative near-term guidance while presenting a credible path to >20% adjusted EBITDA by 2028, so the overall tone is confident with manageable near-term risks.View all CH:KURN earnings summaries

KURN Stock 12 Month Forecast

Average Price Target

CHF32.50

▲(64.14% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"17":"CHF17","34":"CHF34","21.25":"CHF21.3","25.5":"CHF25.5","29.75":"CHF29.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF33.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF32.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF32.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[17,21.25,25.5,29.75,34],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.66,23.455384615384617,24.25076923076923,25.046153846153846,25.841538461538462,26.636923076923075,27.432307692307692,28.22769230769231,29.02307692307692,29.818461538461538,30.613846153846154,31.409230769230767,32.20461538461538,{"y":33,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.66,23.416923076923077,24.173846153846153,24.93076923076923,25.68769230769231,26.444615384615386,27.201538461538462,27.95846153846154,28.715384615384615,29.472307692307695,30.229230769230767,30.986153846153847,31.743076923076924,{"y":32.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.66,23.37846153846154,24.096923076923076,24.815384615384616,25.533846153846156,26.252307692307692,26.970769230769232,27.689230769230768,28.407692307692308,29.126153846153848,29.844615384615384,30.563076923076924,31.28153846153846,{"y":32,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":30.04,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.04,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.12,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.48,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.78,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.08,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.24,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.28,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.3,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.44,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.66,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >